mDF6002
mDF6002 is a IL-12R-Fc fusion protein. mDF6002 induces sustained IFNγ production. mDF6002 exerts tumor-suppressive effects in mouse models of colon cancer and melanoma. mDF6002 can be used for research on solid tumors such as colon cancer and melanoma.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
製品説明
体外実験
Parmacokinetics
体内実験
mDF6006 (0.5 μg; i.p.; once weekly) induces partial responses in 90% of B16F10 melanoma-bearing C57BL/6J mice and drives sustained pharmacodynamic responses in both tumor and serum[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/cJ mice (female, 7-9 weeks old, subcutaneous inoculation with CT26 cells, advanced large tumors averaging 815 mm3)[1]
-
Dosage:1 μg (equimolar to 1 μg rmIL-12)
-
Administration:s.c.; once weekly; 7 weeks
-
Result:Induced complete tumor regression in all 10 treated mice.
Was well tolerated with no body weight loss.
Enabled 9/10 complete responders to reject tumor rechallenge and remain tumor-free, while age-matched naive controls developed progressive tumors.
-
Animal Model:C57BL/6J mice (female, 7-9 weeks old, subcutaneous inoculation with B16F10 cells)[1]
-
Dosage:0.5 μg (equimolar to 0.5 μg rmIL-12)
-
Administration:i.p.; once weekly
-
Result:Induced partial responses in 9/10 treated mice.
Significantly improved survival compared to rmIL-12.
Significantly elevated and protracted levels of IFNγ, CXCL9, CXCL10, CCL5, and TNF-α were detected in both tumor lysates and serum at 72 hours post-dose.
化学情報
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)